NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 100.1 CHF | +0.79% |
|
+3.57% | +17.90% |
| Jul. 12 | S&P 500 Rises Week-to-Week, Closes Near Highs Despite Mixed Inflation Data, Bank Earnings | MT |
| Jul. 12 | Novartis Seeks Squeeze Out Approval at MorphoSys AGM | MT |
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
2024-07-18
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
111.9
USD
Average target price
112.4
USD
Spread / Average Target
+0.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.90% | 228B | |
| +62.66% | 854B | |
| +40.42% | 636B | |
| -4.37% | 361B | |
| +17.16% | 324B | |
| +9.87% | 301B | |
| +15.66% | 247B | |
| +4.21% | 230B | |
| +14.86% | 177B | |
| +0.45% | 164B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Syncona Flags GBP55 Million Valuation Impact as Novartis' Stops Eye Disease Drug Development
